Society of Hematologic Oncology

Free SOHO Membership: www.sohoonline.org

 

Multiple Myeloma
12:41

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Non-Antibody Based Immune Therapy for Multiple Myeloma: T-Cell Therapies to Change MM Therapy, Toxicities Are Manageable, But Must Be Anticipated

FEATURING Nina Shah
  • 239 views
  • November 18, 2019
14:41

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Role of Autologous Stem Cell Transplant in Myeloma in 2019: ASCT Remains SoC and Is Complementary Strategy After Induction w/ Novel Agent Combos

FEATURING Maria-Victoria Mateos
  • 91 views
  • November 18, 2019
14:12

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Myeloma Bone Disease and Management: Optimal Imaging Supports Clinical Care Decisions, Bone Disease Supports Immediate Start of Systemic Therapy

FEATURING Matthew Drake
  • 19 views
  • November 18, 2019
13:17

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

It's Time to Use MRD for Clinical Decision Making: MRD as a Surrogate Marker for PFS/OS, for Maintenance Decision Making, Renal Allografting Patient Qualification, and Solitary Plasmacytomas Definition

FEATURING Jeffrey Wolf
  • 28 views
  • November 18, 2019
14:15

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can Achieve CR, MRD- Patients Have Better Survival, Many MRD Related Specifics Need to Be Defined

FEATURING Thomas Martin
  • 763 views
  • November 18, 2019
  • 6
14:24

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

AL Amyloidosis Therapy and Targets in 2019: Bortezomib Remains Mainstay in Frontline, ASCT in Upfront Is Questionable, Targeted Therapies Offer Promise, IO to Be Proven

FEATURING Suzanne Lentzsch
  • 80 views
  • November 18, 2019
14:43

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Induction Therapy for Newly Diagnosed Multiple Myeloma: What to Use in the Era of Monoclonal Antibodies?

FEATURING Ajay Nooka
  • 110 views
  • November 18, 2019
08:19

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Phase 2 HORIZON Study of Melflufen in Relapsed/Refractory Multiple Myeloma Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety

FEATURING Christopher Maisel
  • 195 views
  • November 18, 2019
  • 1
08:16

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Primary Treatment of Light Chain Amyloidosis with Bortezomib, Lenalidomide, and Dexamethasone (VRD): Effective Regimen Inducing Response w/in 3 mths, Toxicity Manageable

FEATURING Ioanna Dialoupi
  • 19 views
  • November 18, 2019